Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis

Overview of attention for article published in Science Translational Medicine, November 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 32 news outlets
blogs: 1 blog

twitter: 36 X users
facebook: 1 Facebook page

Readers on

mendeley: 79 Mendeley

So far, Altmetric has seen 33 news stories from 32 outlets.

Alterity, UniQuest team up to reverse bacterial resistance to antibiotics

BioSpectrum, 22 Dec 2020

Alterity has secured the worldwide exclusive right to patented technology to develop and commercialize therapies that re-sensitiz…

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

BioTech Gate, 22 Dec 2020

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"…

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Jotup, 21 Dec 2020

Under the licence, Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise…

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

FirstWord Pharma, 21 Dec 2020

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 29 additional news stories.